Navigation Links
Research Gets Closer to Origin of Parkinson's Disease
Date:1/4/2008

Modified protein hastens nerve cell death, scientists say

FRIDAY, Jan. 4 (HealthDay News) -- The nerve cell death that helps drive Parkinson's disease may be triggered by a harmful modification in a particular nerve cell protein, new research reveals.

The modification in question -- an apparently toxic mix of the protein alpha-synuclein and the critical neurotransmitter dopamine -- can be found in all Parkinson's patients, researchers say.

The change short-circuits a process that allows aging nerve cells to stay healthy by purging themselves of damaged molecules, researchers explain in the Jan. 2 online issue of The Journal of Clinical Investigation.

"The general idea is that, in Parkinson's, the neurons accumulate lots of garbage," explained study author Dr. Ana Maria Cuervo, an associate professor in the department of anatomy and structural biology at Yeshiva University's Albert Einstein College of Medicine, in New York City.

"Normally," she said, "this garbage is removed before it builds up, and is dumped into garbage containers called lysosomes, which make sure things can move about the neurons fast and freely."

Such a filtering process for disposing of damaged molecules is known as "autophagy," a term that literally means "self-eating."

"But sometimes, this mechanism fails," Cuervo noted. "And now we have found the reason why. It is because of the formation of this particular modified protein, which acts kind of like chewing gum in the middle of the nerve cell."

"It's not a normal protein," she stressed. "It's very sticky, and any other proteins passing by get stuck to it, so you get all these abnormal things, these stones in the middle of the cell's highways, that are not being removed, and eventually the [brain] cells can't move things around as they should, and they die."

In an earlier effort, the same research team had found that mutant forms of alpha-synuclein -- as opposed to modified forms -- also block the desired breakdown of damaged nerve cell molecules. Such mutant proteins are present in the 5 percent to 10 percent of Parkinson's patients struck with a relatively rare, familial form of the disease.

"But the novelty of our work today is that the modified protein mechanism we found this time will apply to all Parkinson's patients," noted Cuervo. "And so it becomes possible that in the future we can design drugs to improve the function of the garbage containers, the lysosomes, in all Parkinson's patients, and maybe overcome the problem that these nerve cells have handling the modified molecules."

Cuervo and her Einstein colleagues conducted the study, based on laboratory work with male rats, in collaboration with scientists from Columbia University in New York City, the University of Pennsylvania, and Harvard Medical School in Boston.

The National Parkinson Foundation estimates that 1.5 million Americans are affected with Parkinson's disease, the most common degenerative brain disorder affecting movement.

The nerve damage that's characteristic of this incurable disease brings about a dramatic loss of muscle control, typically manifesting as tremors, stiffness, and a loss of balance and agility.

Though optimistic about her work, Cuervo emphasized that translating the latest findings into new preventive and curative interventions will require a lot more research and time.

"I want to be very cautious," she said. "We are far from a final cure. It's not something we can do tomorrow. It's going to take some time. But now we know what the problem is. And we think that we have something, a target, to focus on."

Nonetheless, Dr. Robert Burke, director of the Morris K. Udall Parkinson's Disease Research Center of Excellence at Columbia University, called the new findings a "big step forward."

"Their first finding was only related to the mutant form of the protein which is very rare," he noted. "Whereas here they have shown that dopamine-modified neurons also block the system. This means they now have something that appears applicable to patients with the much more common sporadic form of Parkinson's. And that is very, very helpful."

More information

For more on Parkinson's disease, head to the Parkinson's Disease Foundation.



SOURCES: Ana Maria Cuervo M.D., Ph.D, associate professor, department of anatomy and structural biology, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Yeshiva University, New York City; Robert Burke, M.D., director, Morris K. Udall Parkinson's Disease Research Center of Excellence, Columbia University, New York City; Jan. 2, 2008, Journal of the Clinical Investigation online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. amfAR announces inaugural Mathilde Krim Fellowship Awards for AIDS research
2. Researchers use neuroimaging to study ESP
3. UGA researchers receive $9 million in grants to study barriers to effective addiction treatment
4. Jan Marini Skin Research Gives Familiar Logo a Facelift
5. Researchers seek to make cavity-causing bacteria self-destruct
6. Research suggests new treatment suitable for all patients
7. 2007: A Watershed Year for Lupus Research and Education
8. FASgen Announces New Research Discoveries in Lung Cancer
9. Human factors researchers test voting systems for seniors that can improve voting accuracy and speed
10. New research tools are too complex for easy answers, researchers say
11. Research Offers Promise for Cirrhosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Research Gets Closer to Origin of Parkinson's Disease
(Date:4/29/2016)... ... April 29, 2016 , ... ... Celiac Association (CCA), is pleased to announce the launch of the GFCP ... articles, recipes, and more. The purpose of the GFCP Scoop site ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE ... entirely on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower ... 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... to promote their animal line of probiotics, Petbiotics ™, as they fondly ... turnout of animal rescue groups networking for their non-profit organizations. Animal rescues across ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
Breaking Medicine Technology: